Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of YS-HBV-002 in Chronic Hepatitis B
NCT06162299Phase 1Terminated
- Sponsor
- LakeShore Biopharma Co., Ltd
- Start
- Jul 2024
- Primary completion
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of YS-HBV-002 in Chronic Hepatitis B (CHB) (4 arms), sponsored by LakeShore Biopharma Co., Ltd. Primary endpoints: Incidence of Adverse Events within 30 minutes after vaccination, Incidence of solicited local reactions and 2 more. Started Jul 2024; status: terminated.
02
Drugs
YS-HBV-002
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06162299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06162299.